共 890 条
- [61] Javdan B(2020)Serine proteases at the cutting edge of IBD: focus on gastrointestinal inflammation FASEB J 34 7270-3664
- [62] Lopez JG(2012)Protease-activated drug development Theranostics 2 156-217
- [63] Chankhamjon P(2019)Recent advances in the development of legumain-selective chemical probes and peptide prodrugs Biol Chem 400 1529-176
- [64] Lee YCJ(2020)Protease-activated prodrugs: strategies, challenges, and future directions FEBS J 287 1936-3950
- [65] Hull R(2014)Mechanism-based inhibitors of glycosidases: design and applications Adv Carbohydr Chem Biochem 71 297-171
- [66] Wu Q(2013)The abundance and variety of carbohydrate active enzymes in the human gut microbiota Nat Rev Microbiol 11 497-526
- [67] Wang X(2015)Structure and inhibition of microbiome b-glucuronidases essential to the alleviation of cancer drug toxicity Chem Biol 22 1238-901
- [68] Chatterjee S(2009)Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile Int J Exp Pathol 90 489-1576
- [69] Donia MS(2006)Pharmacogenetics of irinotecan metabolism and transport: an update Toxicol In Vitro 20 163-1733
- [70] Kerimi A(2001)Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients Clin Cancer Res 7 1136-298